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BACKGROUND: We assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouracil (5-FU), leucovorin (FA)
and oxaliplatin (L-OHP) (chrono-IFLO) administered as neoadjuvant chemotherapy to increase the resectability of colorectal liver
metastases.
METHODS: This was a phase II prospective trial with rate of liver metastases resection as primary end point. Forty-three patients with
unresectable metastases were enroled: 9 with metastases 45cm; 29 with multinodular (44) disease; 1 with hilar location; 4 with
extrahepatic lung disease. Treatment consisted of cetuximab at day 1 plus chronomodulated irinotecan 5-FU, FA and L-OHP for
2–6 days every 2 weeks. After the first 17 patients, doses were reduced for irinotecan to 110mgm
 2, 5-FU to 550mgm
 2 per day
and L-OHP to 15mgm
 2 per day.
RESULTS:Macroscopically complete resections were performed in 26 out of 43 patients (60%) after a median of 6 (range 3–15) cycles.
Partial response was noticed in 34 patients (79%). Median overall survival was 37 months (95% CI: 21–53 months), with a 2-year
survival of 68% in the entire population, 80.6% in resected patients and 47.1% in unresected patients (P¼0.01). Grade 3/4 diarrhoea
occurred in 93% and 36% of patients before and after dose reduction.
CONCLUSION: Cetuximab plus chrono-IFLO achieved 60% complete resectability of colorectal liver metastases.
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Surgery can offer the potential for cure in patients with liver
metastases from colorectal cancer (CRC). However, B80% of these
patients present with initially unresectable metastatic liver disease
(Adam et al, 2004). Historically, patients with unresectable
colorectal liver metastases received chemotherapy with palliative
intent but there is growing evidence that neoadjuvant chemo-
therapy can downsize tumours and facilitate potentially curative
resection (Bismuth et al, 1996; Adam et al, 2004; Folprecht et al,
2005; Alberts et al, 2005). In a cohort of 1439 consecutive patients,
12.5% of patients with initially unresectable colorectal liver
metastases were rescued to liver surgery following treatment with
5-fluorouracil (5-FU), leucovorin (FA) plus irinotecan (CPT-11) or
oxaliplatin (L-OHP) or both, with a 5-year survival rate of 33%
(Adam et al, 2004). In the past few years, we and others have
developed a chronomodulated infusion schedule of CPT-11 plus
5-FU/ FA and L-OHP (chrono-IFLO) with the aim of optimise
delivering of all active drugs together based on circadian tolerability
(Granda et al, 2002; Garufi et al,2 0 0 3 ;G h o l a met al, 2006; Garufi
et al, 2007; Bouchahda et al, 2009). Indeed the tolerability and the
efficacy of chemotherapeutic drugs, as well as of radiotherapy, vary
50% of more as a function of dosing time in mice or rats (Le ´vi, 2001).
Cetuximab is an IgG1 monoclonal antibody that specifically
targets the epidermal growth factor receptor (EGFR) and that
competitively blocks the binding of epidermal growth factor and
other ligands, inhibiting the cellular pathways involved in the
processes of cellular proliferation, angiogenesis and metastasis
(Ciardiello and Tortora, 2008). Detection of positive EGFR
expression by immunostaining does not reliably predict clinical
outcome in patients receiving cetuximab; however, mutations in
the genes of the signaling effectors downstream of EGFR, such as
KRAS, are central to the progression of CRC and have emerged as
important predictive markers of resistance to cetuximab treatment
(Siena et al, 2009). The addition of cetuximab to doublet
chemotherapy regimens such as FOLFIRI (5-FU, FA, CPT-11) or
FOLFOX (5-FU, FA, L-OHP) has been shown to increase response
rates, and prolong progression-free survival (PFS) and overall
survival (OS) times in the first-line treatment of patients with
metastatic CRC and KRAS wild-type tumours (Bokemeyer et al,
2009; Van Cutsem et al, 2009). In these trials, the resectability rate
for liver metastases was improved by the addition of cetuximab to
chemotherapy, when retrospectively evaluated.
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hepatic resection (POCHER) trial was to investigate the resection
rate of patients with colorectal liver metastases considered
unresectable following neoadjuvant treatment with cetuximab plus
chrono-IFLO
PATIENTS AND METHODS
Patients
In all, 43 patients referred to our centres (26 patients to Regina
Elena Cancer Institute and 17 patients to S Maria degli Angeli
Hospital) between July 2006 and September 2008 were enrolled in
this study; they presented with histologically confirmed colorectal
adenocarcinoma, Eastern Cooperative Oncology Group Perfor-
mance Status score of 0–1, age X18 and p75 years, and a life
expectancy of X3 months. Patients were considered unsuitable for
resection of their liver metastases according to the following
criteria: size larger than 5cm, multinodular disease (44), hilar
location and presence of extrahepatic disease (except micro-
nodular limited lung metastases). Patients with 43 metastases
who had received chemotherapy to stabilise their liver disease
before surgery were considered eligible for the trial as well as
patients who presented with large liver metastases at the time of
resection of a primary extraperitoneal rectal cancer. Assessment of
liver involvement was performed by combined use of spiral computed
tomography (CT) and ultrasound, which had to be performed
within 1 month of the beginning of treatment. Magnetic resonance
imaging, positron emission tomography/CT scans and intraopera-
tive ultrasound were used if necessary. All staging procedures were
conducted in the participating centres and all cases were discussed
for eligibility after consultation with medical oncologists, radio-
logists and surgeons. Other inclusion criteria were adequate
haematological, liver and renal function. Exclusion criteria were
brain and bone metastases, whereas micronodular limited lung
disease could be admitted, considering the possibility of chemo-
therapy control followed by resection if needed; radiotherapy
within 4 weeks before the study entry; previous exposure to
anti-EGFR monoclonal antibodies; clinically relevant coronary
artery disease or history of a myocardial infarction in the last 12
months, acute or sub-acute intestinal occlusion or history of the
inflammatory bowel disease; or any concurrent malignancy other
than non-melanoma skin cancer or cervix in situ carcinoma. The
protocol was approved by the local ethic committees of the
individual centres and was registered with Eudaract number
2005-006205-28. All patients provided written informed consent.
The trial design is outlined in Figure 1.
Treatment
On day 1 of each 14-day cycle, cetuximab was infused at an initial
dose of 400mgm
 2 and then 250mgm
 2 weekly. Irinotecan
130mgm
 2 was given on day 2 as a 6-h chronomodulated
infusion, peak time at 1300 hours. From day 3–6 all patients
received a 4-day chronomodulated infusion of 5-FU 600mgm
 2
per day and levo-leucovorin 150mgm
 2 per day from 2215 hours
to 0945 hours, with peak delivery at 0400 hours and oxaliplatin
20mgm
 2 per day from 1015 hours to 2145 hours, with peak
delivery at 1600 hours. Treatment was administered using
a four-reservoir, multichannel, programmable in-time pump
(Melodie, Aguettant, France) in an outpatients setting. An interim
analysis for toxicity was performed after the first 17 patients
had been treated and dose reductions were implemented, such
that all subsequent patients received irinotecan 110mgm
 2,
5-FU 550mgm
 2 per day and oxaliplatin 15mgm
 2 per day.
In the event of predefined toxic effects related to chemotherapy
or cetuximab, protocol-specified treatment modifications were
allowed.
Tumour response was assessed every four cycles according
to Response Evaluation Criteria In Solid Tumours (RECIST)
(Therasse et al, 2000). Resection was evaluated and intended to be
performed after eight cycles and within 45 days of the last
treatment cycle. Patients with unresectable tumours continued
treatment until disease progression, unacceptable toxicity or
patient refusal. Following resection, patients were continued on
treatment for an additional six cycles.
Assessments
The primary end point was resection rate of liver metastases,
which was evaluated in all patients. Secondary end points were rate
of complete pathologic responses, response rates, PFS and OS.
Response rate was calculated based on RECIST for the intention-
to-treat population, which included all patients who had received
at least one course of therapy. The PFS was calculated for all
patients from the day of study entry until the date of progression
of disease. Time to relapse was the interval between surgery and
the first recurrence of disease. Patients who did not progress were
censored at the last date they were known to be alive. Patients who
died of disease and for whom a date of progression was not
available were considered to have progressed on the day of their
death. Safety was an additional secondary end point, and all
toxicities episodes were graded according to the National Cancer
Institute Common Toxicity Criteria Version 3.
Surgery
Limited or major hepatic resection was considered for the analysis
only when the extent of resection was complete (R0). The R1
(margin positive) and R2 (unresectable) resections were recorded.
Ablative techniques were allowed in addition to surgery in the
operative room.
Patient with non-resectable colorectal liver metastases
Evaluation of inclusion/exclusion criteria
informed consent
Treatment with CPT11/5FU-FA/L-OHP + cetuximab
first evaluation of response after four cycles
Partial response, disease stabilization: other four cycles
Evaluation for resectability
Non-resectable Resectable
Surgery not before than 
eight cycles and within
 45 days from the
 last cycle
Chemo + cetuximab
for six cycles
Chemo + cetuximab will be
continued until PD,
unacceptable toxicity or
patient refusal
Figure 1 Trial design. 5-FU, 5-fluorouracil; CPT11, irinotecan; FA/L,
levo-leucovorin; L-OHP, oxaliplatin; PD, progressive disease.
Chemotherapy cetuximab liver metastases
C Garufi et al
1543
British Journal of Cancer (2010) 103(10), 1542–1547 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe EGFR and KRAS testing
EGFR expression was assessed by immunohistochemistry, but was
not an eligibility criterion. It was evaluated by EGFR-pharmDx-kit
(Dako, Milan, Italy) and was scored considering percentage of
staining with a cut off of 10% of cells.
The effect of KRAS mutations on cetuximab activity was not
known at the time the study was designed; tumour KRAS mutation
status was subsequently assessed retrospectively on patient tumour
samples by direct sequencing.
Statistical analysis
The sample size calculation was based on the two-step Simon
minimax design. Chrono-IFLO plus cetuximab would be consid-
ered ineffective and the trial would be stopped if the resection rate
was p10%. Chrono-IFLO plus cetuximab would be considered
effective and the study would be pursued if the resection rate was
X25%. On the basis of an a level of 5% and a power of 80%, a
minimum of 22 subjects had to be enrolled during the first step of
the study and 18 subjects during the second step (40 subjects
overall). The PFS and OS were calculated based on Kaplan–Meier
curves. Differences in toxicity before and after dose reduction were
calculated by the McNemat test for paired data.
RESULTS
A total of 43 patients were enrolled and evaluated (Table 1).
Median age was 61 (range 33–75) years and the majority of
patients were male (63%). Most patients had undergone resection
of their primary tumour (90%) and most had synchronous liver
disease (81%). Multinodular involvement of 44 lesions was the
predominant reason for unresectability (68%). Four patients had
extrahepatic limited lung disease. Of the 37 patients evaluable for
tumour KRAS mutation status, 81% had KRAS wild-type tumours.
In six patients it was not possible to collect tumour samples.
After an interim analysis in the first 17 patients, doses were
reduced because of the unacceptable toxicity. The reduction for all
patients occurred within the third cycle. One case of sepsis was
observed, one patient had severe cardiac toxicity with arrhythmias
leading to treatment interruption, and another patient developed
renal failure. One of the 17 patients refused to continue therapy
because of the toxicity. Diarrhoea was the major treatment toxicity
reaching grade 3/4 in 93% patients, and was often accompanied
with abdominal pain (33% of patients; Table 2). Grade 2/3 afebrile
neutropenia was found in 19% of patients. After dose reduction,
there was a significant reduction in the proportion of patients who
experienced diarrhoea, although grade 3/4 diarrhoea was still
present in more than one-third of patients and one-quarter had
grade 2 diarrhoea (Table 2). There were numerically fewer cases of
grade 2–3 neutropenia after dose reduction (19 vs 13%) and no
relevant thrombocytopenia or anaemia was observed. Grade 2–3
sensory neuropathy was not recorded in any of the 43 patients.
All 43 enroled patients were evaluated for response and
resectability. Partial responses were obtained in 34 patients, with
an objective response rate of 79.1% (95% CI: 66.9–91.2%). All
resected patients had obtained a partial response. In all, 26 patients
underwent radical liver surgery after neoadjuvant chemotherapy
with cetuximab plus chrono-IFLO, with a R0 resection rate of 60%
(95% CI: 45.8–75.1) fulfilling the primary end point. Two patients
underwent R1 resection and six patients (14%) underwent
explorative laparoscopy and disease was judged unresectable
(R2). Of the 26 patients who underwent radical surgery, 13 (30%
of all patients) had multiple wedge resections, 9 (21%) underwent
two-step hepatectomies, 3 (7%) had right hepatectomies and 1 (2%)
had a left hepatectomy. Two patients received radiofrequency
ablation in addition to surgery. Two complete pathological
responses were observed in the resected specimens. Stable disease
was achieved in five patients, three patients discontinued because
of the toxicity and one refused to continue before study evaluation.
The median number of cycles per patient was 10 (range 2–18).
The median before surgery was 6 (range 3–15) rather than the
8 courses planned, because of the rapid tumour shrinkage (Figure 2).
The median time from last course of chemotherapy to surgery was
5 weeks (range 1–11). The median number of cycles after surgery
was 5 (range 1–6). Median time of treatment for all patients was
28 weeks (range 2–59). A total of 20 patients completed the 14 cycles
of treatment planned in the trial design. Dose reduction did not
affect response rate (76.5% in the first 17 patients vs 80.8% in
subsequent patients enroled, P¼0.73) and resection rate (62.6 vs
58.8%, P¼0.47). Moreover toxicity did not affect time to surgery
(P¼0.23).
Regarding the four patients with extrahepatic lung disease, only
one was resected for liver and lung metastases, one rapidly progressed
in the lung after liver resection and two were never resected.
Table 1 Patient characteristics at baseline
No. of patients %
Entire population 43 100
Median (range) age (years) 61 (33–75)
Male/female 27/16 63/37
Colon/rectum 34/9 79/21
Primary tumour resected 39 90
Synchronous metastases 35 81
Liver involvement 425% 34 79
Unresectability
Size 45cm 9 21
Multinodular 442 9 6 8
Hilar location 1 2
Extrahepatic disease 4 9
Median (range) CEA, ngml
 1 55 (1–6600)
Median (range) CA19-9, Ul
 1 92 (2–66440)
EGFR (extent of staining)
08 2 3
14 1 1
21 8 5 2
35 1 4
KRAS wild type/mutant
a 30/7 81/19
Abbreviations: CA19–9¼carbohydrate antigen 19–9; CEA¼carcinoembryonic
antigen; EGFR¼epidermal growth factor receptor.
an¼37
Table 2 Major grade 2–4 toxicities before and after dose reductions
Patients experiencing toxicity (%)
Type of toxicity Grade
Before dose
reduction
After dose
reduction P-value
Diarrhoea 2 6 26 NS
3 81 35 0.005
4 13 1 0.006
Abdominal pain 2 31 25 NS
3 2 7 0.05
40 0 N S
Fatigue 2 43 37 NS
38 1 2 N S
42 0 N S
Nausea/vomiting 2 50 44 NS
31 2 1 0 N S
41 0 N S
Afebrile neutropenia 2 12 7 NS
37 6 N S
Cutaneous rash 2 50 66 NS
32 0 1 5 N S
Abbreviation: NS¼not significant.
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7 out of 43 (16%) patients alive without recurrence, 17 out of
43 (39.5%) alive with recurrence, two patients lost to follow-up
and 17 out of 43 (39.5%) patients who died because of the disease
progression. Among seven patients alive without recurrence, five
patients were KRAS wild type representing the 16.6% (5 out of 30) of
all KRAS wild-type patients, whereas two patients were KRAS muted.
The PFS for all patients was 14 months (95% CI: 11–17 months;
Figure 3). For those patients who were resected, PFS was 15 months
(95% CI: 12–19 months; Figure 3), whereas PFS was 9 months
(95% CI: 1–17 months) for those patients who were not resected.
The median time from surgery until relapse was 11 months
(95% CI: 9–13 months). After liver surgery, 10 out of 26 patients
(38%) had disease recurrence in the liver, 4 out of 26 (15%)
patients had disease recurrence outside the liver (one presented
already extrahepatic disease at study entry) and 6 out of
26 patients (23%) had disease recurrence both in the liver and
outside (none of these 6 patients presented extrahepatic disease at
Figure 2 Pre-treatment (A, B, C) and after six courses (D, E, F) spiral TC-scan of a patient submitted to a two-step hepatectomy (she is free of disease
after 34 months of follow-up).
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Figure 3 Kaplan–Meier curves of progression-free survival (PFS) and overall survival. (A) The PFS in the entire population (n¼43); (B) PFS in resected
(unbroken line) and not resected (broken line) patients. (C) Overall survival in the entire population (n¼43); (D) overall survival in resected (unbroken line)
and not resected (broken line) patients.
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(95% CI: 21–53 months), with 68.2% of patients alive at 2 years in
the entire population, 80.6% in resected patients and 47.1% in
non-resected patients (P¼0.01; Figure 3).
In those patients with liver-only recurrent disease, it was
possible to perform a re-hepatectomy in 5 patients; 19 patients
received second-line chemotherapy and 7 patients received third-
line chemotherapy. Bevacizumab plus FOLFIRI or FOLFOX was
used in 12 patients as second- or third-line therapy. Seven patients
received FOLFOX or XELOX (capecitabine plus oxaliplatin);
various other treatments including locoregional therapies were
used in the remaining patients.
DISCUSSION
This is the first study that tests the relevance of cetuximab in
addition to a triplet combination as first-line treatment for
metastatic colorectal cancer and uses the rate of macroscopic
resection of liver metastases as main end point.
In the POCHER trial, we showed that intensive chemotherapy
with chrono-IFLO plus cetuximab resulted in high response rates,
rapid tumour shrinkage and a resection rate of 60%. In addition,
the combination produced an estimated median OS for all patients
of 37 months after a median follow-up of 22 months. The main
treatment toxicity was severe diarrhoea, which affected most of the
patients before dose reduction and was still present in more than
one-third of patients after dose reductions. Neutropenia was not
common and neurotoxicity was absent. Dose reduction due to
toxicity did not compromise response rate, resection rate and time
to surgery.
The results of the POCHER trial extend the findings of the recent
CELIM trial of cetuximab in combination with either FOLFOX
(n¼56) or FOLFIRI (n¼55) as neoadjuvant therapy in patients
with unresectable colorectal liver metastases (Folprecht et al,
2010). Resection rates were 38% with cetuximab plus FOLFOX and
30% with cetuximab plus FOLFIRI, with a confirmed partial or
complete response noticed in 68 and 57% of the patients,
respectively. Toxicity was acceptable in the CELIM trial, with
72% of all patients experiencing at least one episode of grade 3/4
toxicity; 23% of patients experienced grade 3/4 neutropenia and
14% experienced grade 3/4 diarrhoea. Other studies have provided
evidence of the effectiveness of cetuximab plus doublet chemo-
therapy for unselected populations of patients with advanced
CRC. In the CRYSTAL trial, the addition of cetuximab to FOLFIRI
showed an increase in the resection rate from 4.5 to 9.8% in a
subgroup of patients with liver-limited disease (Van Cutsem et al,
2009). In the OPUS study, in which FOLFOX±cetuximab was
used, the resection rate for liver metastases doubled from 2.4 to
4.7% in the cetuximab group (Bokemeyer et al, 2009).
The use of a triplet rather than a doublet chemotherapy schedule
was justified by the results obtained by Falcone et al (2007) in a
randomised study comparing triplet FOLFOXIRI chemotherapy
with FOLFIRI, in the absence of cetuximab. They found the
resection rate to be greater in the FOLFOXIRI arm (36% vs 12%;
P¼0.017) in patients with metastases confined to the liver.
Treatment with FOLFOXIRI resulted in a 5-year survival rate of
42%. Recently the same group added bevacizumab to the
FOLFOXIRI regimen with 40% resection rate of liver metastases
in an unselected population. Table 3 compares our data with other
relevant experiences in this field.
One possible explanation for the high activity of cetuximab plus
chemotherapy in the treatment of patients with liver metastases
could be the high incidence of patients with KRAS wild-type
tumours; 70 and 80% in the CELIM and POCHER trials,
respectively, which is higher than the B60% usually observed in
CRC patient populations. This point warrants further validation in
a patient population with liver only metastases. Other potential
reasons, such as a greater immunological effect of cetuximab in the
liver, could be speculated.
Another feature of this trial was the use of a chronomodulated
schedule. The EORTC trial 05963 comparing chronomodulated vs
conventional delivery of FOLFOX showed male patients receiving a
chronomodulated regimen to have a higher response rate and
longer PFS and OS times vs conventional delivery; however,
women had significantly longer PFS and OS using conventional
delivery (Giacchetti et al, 2006). Interestingly, in recent meta-
analysis of three randomised trials the rate of complete macro-
scopic resections of liver metastases was 12.5% in men using
chronomodulated delivery vs 7.8–8.5% in men using conventional
delivery, or in women on either schedule (Levi et al, 2009). In an
unselected series of patients treated with chrono-IFLO plus
cetuximab, we observed more than 20% dose reduction due to
diarrhoea in 47% of females vs 12% of males (P¼0.03) (Garufi
et al, 2010). To increase tolerability of this schedule, we could
consider irinotecan pharmacogenetics, identification of better
circadian peaks for women and delivering of treatment every 3
weeks in frail patients. Moreover, we could not preclude the use of
intra-arterial ‘adjuvant’ chemotherapy as postoperative treatment
to reduce intrahepatic recurrence rate.
A randomised phase II trial with cetuximab plus FOLFOX or
FOLFIRI vs chrono-IFLO and a different trial testing various
chronotherapeutic schedules could helpful to better define our
strategy and chronobiological profile.
In conclusion, in the POCHER trial, the combination of an
intensive chemotherapy regimen of chronomodulated IFLO plus
cetuximab was associated with high response rates and facilitated
radical resections in 60% of patients with colorectal liver
metastases, providing improved long-term survival.
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Table 3 Chemotherapy trials of neoadjuvant chemotherapy for colorectal cancer liver metastases
Schedule
Selected
patients
No. of
patients RR (%)
R0 resection
(%)
Cetuximab plus doublets Cetuximab+FOLFIRI (Van Cutsem, et al, 2009) No 132 46.9 4.8
Cetuximab+FOLFOX4 (Bokemeyer et al, 2009) No 169 46.0 4.7
Cetuximab+FOLFOX or FOLFIRI (Folprecht et al, 2010) Yes 111 85.0 (Oxa)-66.0 (CPT) 34
Triplets FOLFOXIRI (Falcone et al, 2007) No 39 66 36
FOLFOXIRI (De la Ca ´mara et al, 2004) Yes 39 64 43
FOLFOXIRI (Ychou et al, 2008) Yes 34 70 26
Monoclonal antibody plus triplets Cetximab+chrono-IFLO (Garufi et al, present study) Yes 43 79.1 60
Bevacizumab+FOLFOXIRI (Masi et al, 2010) No 30 80 40
Abbreviations: CPT¼irinotecan; Oxa¼oxaliplatin; RR¼response rate; R0 resection¼radical resection.
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